Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 CAD | -4.76% | -3.85% | -25.93% |
Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.93% | 103M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.09% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- NGEN Stock
- News NervGen Pharma Corp.
- NervGen Pharma Reports Dosing of All Subjects in Phase 1 Clinical Trial of Drug Candidate NVG-291